Lo mejor del Congreso 2019 de la Sociedad Europea de Cardiología

The European Congress of Cardiology is one of the most relevant events of the world cardiology community. It was held from August 31 to September 4 in the heart of Paris, France, the central theme being global cardiovascular health. As usual, it was attended by more than 30,000 professionals and prominent guests. Updates of several clinical practice guides and important scientific papers were presented. These undoubtedly will impact in the treatment of patients with cardiovascular pathology.Below we present a brief summary of some of the trials presented: A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial